Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Ranica

23 clinical trials in Ranica, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Ranica at a glance
23
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

23 trials in Ranica

Open in trial search

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zigakibart
  • Sponsor:Novartis Pharma AG

Renal disorder+1

Recruiting

A study to evaluate the safety of ADX-038 in patients with complement-mediated kidney disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ADX-038
  • Sponsor:Adarx Pharmaceuticals Inc.

Obinutuzumab treatment for adults with frequently relapsing idiopathic nephrotic syndrome who are dependent on rituximab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iohexol
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited

Study of Atacicept Treatment for Patients with Multiple Autoimmune Glomerular Diseases

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Atacicept
  • Sponsor:Vera Therapeutics Inc.

Study on Long-Term Effects of Iptacopan in Patients with C3 Glomerulopathy or Idiopathic Immune-Complex Membranoproliferative Glomerulonephritis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study on Switching from Anti-C5 Antibody Therapy to Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Chronic kidney disease

Not yet recruiting

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zigakibart
  • Sponsor:Novartis Pharma AG

Nephropathy

Not recruiting

A Study of ALXN1920 Compared to Placebo in Adults with Primary Membranous Nephropathy at High Risk for Disease Progression

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ALXN1920
  • Sponsor:Alexion Pharmaceuticals Inc.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Ranica

What the registry says about research in the country

01 Glomerulonephritis Studies

Innovative research focusing on membranoproliferative glomerulonephritis and related conditions, evaluating novel therapeutic approaches including iptacopan and pegcetacoplan for treating various forms of kidney inflammation.

  • IC-MPGN Treatment Evaluation
  • C3 Glomerulopathy Research
  • Post-Transplant Recurrence Studies

Multiple trials aim to reduce proteinuria and improve long-term kidney function outcomes.

02 Nephropathy Research

Comprehensive studies examining treatments for IgA Nephropathy and membranous nephropathy, including investigations of sparsentan and specialized antibody therapies for patients resistant to conventional treatments.

  • Primary Membranous Nephropathy
  • IgA Nephropathy Interventions
  • Antibody-Based Treatments

Focus on proteinuria reduction and preservation of renal function in various nephropathy types.

03 Chronic Kidney Disease

Advanced research into non-diabetic chronic kidney disease, exploring new therapeutic options including finerenone and investigating treatments for complications like hyperkalemia.

  • Disease Progression Prevention
  • Hyperkalemia Management
  • Long-term Kidney Function

Studies aim to delay disease progression and improve standard of care outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.